{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:52Z","timestamp":1786119652035,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"DOI":"10.1097\/qai.0b013e31820a820f","type":"journal-article","created":{"date-parts":[[2011,2,11]],"date-time":"2011-02-11T03:03:23Z","timestamp":1297393403000},"page":"S62-S67","source":"Crossref","is-referenced-by-count":21,"title":["Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine\/Naloxone in HIV-Infected Opioid-Dependent Patients"],"prefix":"10.1097","volume":"56","author":[{"given":"Pamela","family":"Vergara-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jo","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Botsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Altice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210131","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment.","volume":"36","author":"Netherland","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"Suppl 4","key":"R2-10-20210131","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1086\/508182","article-title":"A trial of integrated buprenorphine\/naloxone and HIV clinical care.","volume":"43","author":"Sullivan","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R3-10-20210131","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-8278(00)00050-7","article-title":"Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation.","volume":"34","author":"Berson","year":"2001","journal-title":"J Hepatol"},{"key":"R4-10-20210131","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1345\/aph.1L628","article-title":"Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis.","volume":"43","author":"Peyriere","year":"2009","journal-title":"Ann Pharmacother"},{"key":"R5-10-20210131","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/00042737-200410000-00013","article-title":"Acute hepatitis due to buprenorphine administration.","volume":"16","author":"Herve","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R6-10-20210131","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/10550490050148099","article-title":"Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine.","volume":"9","author":"Petry","year":"2000","journal-title":"Am J Addict"},{"key":"R7-10-20210131","first-page":"257","article-title":"Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.","volume":"26","author":"Iribarne","year":"1988","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 4","key":"R8-10-20210131","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1086\/508188","article-title":"Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir\/ritonavir, and ritonavir.","volume":"43","author":"McCance-Katz","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R9-10-20210131","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/QAI.0b013e3181d3cad3","article-title":"Pharmacokinetic interactions between burprenorphine\/naloxone and once daily lopinavir\/ritonavir.","volume":"54","author":"Bruce","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-10-20210131","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.qai.0000219769.89679.ec","article-title":"Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice.","volume":"41","author":"Bruce","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R12-10-20210131","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.drugalcdep.2007.06.007","article-title":"Interaction between buprenorphine and atazanavir or atazanavir\/ritonavir.","volume":"91","author":"McCance-Katz","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"R13-10-20210131","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/QAI.0b013e318209740f","article-title":"A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.","volume":"56","author":"Cheever","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R14-10-20210131","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/QAI.0b013e3182097426","article-title":"A multi-site evaluation of integrated buprenorphine\/naloxone and HIV treatment: overview of the BHIVES collaborative.","volume":"56","author":"Weiss","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R15-10-20210131","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/QAI.0b013e318209d3b9","article-title":"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine\/naloxone (bup\/nlx) and HIV care.","volume":"56","author":"Chaudhry","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R16-10-20210131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/QAD.0b013e328013db9c","article-title":"Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?","volume":"21","author":"Cicconi","year":"2007","journal-title":"AIDS"},{"issue":"Suppl 1","key":"R17-10-20210131","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone.","volume":"56","author":"Fiellin","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R18-10-20210131","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-anfected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study.","volume":"56","author":"Altice","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"R19-10-20210131","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/QAI.0b013e31820a9a66","article-title":"The cost of integrated HIV care and buprenorphine\/naloxone treatment: results of a cross-site evaluation.","volume":"56","author":"Schackman","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R20-10-20210131","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/00952990701653875","article-title":"Case series on the safe use of buprenorphine\/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases.","volume":"33","author":"Bruce","year":"2007","journal-title":"Am J Drug Alcohol Abuse"},{"key":"R21-10-20210131","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone.","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"R22-10-20210131","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0376-8716(00)00227-1","article-title":"Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days.","volume":"64","author":"Gross","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"R23-10-20210131","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1360-0443.2001.9668234.x","article-title":"Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens.","volume":"96","author":"Petry","year":"2001","journal-title":"Addiction"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e31820a820f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:05Z","timestamp":1786041905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201103011-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":22,"journal-issue":{"issue":"Supplement 1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31820a820f","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,1]]}}}